Take Homes in Prostate Cancer

Take Homes in Prostate Cancer

Source: Healio Interview
Disclosures: Dorff reports consulting for Astellas, AstraZeneca, Janssen, Pfizer and SeaGen.
June 23, 2022
1 min watch
Save

VIDEO: MAGNITUDE study shows impact on infrequent DNA repair mutations in prostate cancer

Source: Healio Interview
Disclosures: Dorff reports consulting for Astellas, AstraZeneca, Janssen, Pfizer and SeaGen.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this video, Tanya Dorff, MD, head of the genitourinary cancers program at City of Hope, discusses data from the MAGNITUDE study in prostate cancer presented at ASCO Annual Meeting.

Dorff talks about less frequent mutations in DNA repair highlighted by the study, which provided data on poly(ADP-ribose) polymerase (PARP) inhibition’s positive effects on those mutations.

“When clinicians encounter these less common DNA repair alterations, it is acceptable and perhaps even appropriate to use olaparib in those patients, and as we start to see more data and patients treated, we’ll start to get greater confidence,” Dorff said.

Reference:

  • Chi K, et al. Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.